CID1633
Atezolizumab A Promising Option for Early-Stage NSCLC
In patients with resected stage II-IIIA non-small cell lung cancer (NSCLC), atezolizumab showed a...
Sex Differences in Anti-PD-1/Anti-PD-L1 Treatment for NSCLC
For the treatment of non-small cell lung cancer (NSCLC), anti-PD-1/anti-PD-L1 monotherapy is highly effective in men but not in women, even in NSCLC that expresses high PD-L1 levels, explain Fabio Conforti, MD, and Laura Pala,...
Postoperative Nutrition May Affect Early-Stage NSCLC Outcomes
Postoperative changes in nutritional status may be important in early-stage NSCLC outcomes, according to a study published in PLoS One. Although preoperative nutritional status is an important host-related prognostic factor for...
Gene Expression Profile Improves Early-Stage NSCLC Survival
A clinically certified gene expression profile improved survival in a cohort of patients with stage I-IIA NSCLC by identifying those likely to benefit from adjuvant intervention, independent of epidermal growth factor receptor...
Segmentectomy Bests Lobectomy in Pulmonary Function Preservation
Segmentectomy results in better preservation of pulmonary function compared with lobectomy in patients with early-stage NSCLC, according to a study published in The Journal of International Medical Research. Although...
Atezolizumab Favorable After Adjuvant Chemotherapy
Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with resected early-stage NSCLC, according to a study published in The Lancet. Researchers who evaluated adjuvant atezolizumab versus best...
Interstitial Lung Abnormalities Linked With Post-Op Complications in NSCLC
Pretreatment fibrotic interstitial lung abnormalities (ILAs) were associated with postoperative pulmonary complications (PPC)s, higher postoperative mortality, and longer hospital stay in a cohort of elderly patients undergoing...
IMpower010: Atezolizumab Extends DFS in NSCLC
Efficacy pronounced for patients with PD-L1 expression on 50% or more tumor cells Use of the...
Patient-Reported Outcomes
This study states that Historically, the prognosis for patients with metastatic non–small-cell lung cancer (NSCLC) has been poor, with 5-year survival of approximately 6%.1 However, the introduction of immune checkpoint...
Immune Checkpoint Inhibitor Therapy
This article has been reviewed so that we could detect how Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the management of a wide variety of malignancies. ICIs, such as monoclonal antibodies...
